ORION-4 is a research study which aims to find out if a new cholesterol lowering injection safely reduces the risk of heart attacks and strokes in people who have already had one of these conditions, or who have had an operation or procedure to unblock their arteries.
The study is coordinated by the University of Oxford and co-sponsored by The University of Oxford and The Medicines Company in collaboration with researchers at the TIMI Study Group at Brigham and Women’s Hospital in Boston, USA.
About 15,000 people aged 55 years or older will take part in this study. Half will get inclisiran injections and half will get dummy (inactive placebo) injections. Which treatment a person gets is decided by chance and neither participants nor their doctors will know which treatment they are given (ie this is a 'double-blind' randomised trial). Participants are asked to stay in the study for about 5 years.
Our team
-
Louise Bowman
Professor of Medicine and Clinical Trials, and Honorary Consultant Physician (Lipidology)
-
Jonathan Emberson
Professor of Medical Statistics and Epidemiology
-
Martin Landray
Professor of Medicine and Epidemiology
-
Marion Mafham
Associate Professor, Heart Studies Group
-
Michelle Nunn
Senior Study Administrator
-
David Preiss
Professor of Metabolic Medicine and Clinical Trials
